Jan. 17, 2021, 12:07 a.m. EST

Chronic Granulomatous Disease Market 2021 Outlook, Recent Trade Survey, Key Challenges, Future Opportunities and Geographic Analysis

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

Jan 17, 2021 (Heraldkeepers) --  

Market Scenario:

The Global Chronic Granulomatous Disease Market is expected to grow at a steady pace over the forecast period. The chronic granulomatous disease is a rare inherited disorder which is passed on from parents to their children. People with this disease have weak immune systems which leave their body vulnerable to chronic inflammation and frequent bacterial and fungal infections. The symptoms of this disease develop in the infancy or in the early childhood. The symptoms of this disease vary from person to person. Some common signs and symptoms may include frequent bacterial and fungal infections, swollen lymph nodes, persistent diarrhea, abscesses involving liver, lungs, spleen, bones, or skin.

Factors such as the growing prevalence of rare diseases, increasing expenditure on healthcare sector in the developed economies, and increasing research and development activities are anticipated to drive the growth of the market. However, expensive diagnostic tests and lack of awareness about the disease in the developing and underdeveloped economies may hinder the market growth over the forecast period. For instance, the cost of genetic testing ranges from USD 100 to USD 2,000.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6447

Key players

Pfizer, Inc., InterMune, Inc., Novartis AG, Lonza Group, GlaxoSmithKline Plc, Eli Lilly and Company, Janssen Pharmaceuticals, Merck KGaA, Osiris Therapeutics, Inc, JCR Pharmaceuticals Co., Ltd., Maxcyte Inc., and Horizon Pharma Plc are some prominent player in the market.


The global chronic granulomatous disease market has been segmented into type, diagnosis, treatment, and end user.

The market, on the basis of type, is segmented into X-linked chronic granulomatous disease and autosomal recessive chronic granulomatous disease.

The market, by diagnosis, has been segmented into neutrophil function tests, genetic testing, prenatal testing, and others.

The market, by treatment, has been segmented into infection management, interferon-gamma, stem cell transplantation, and others. The infection management segment has been further segmented into trimethoprim, sulfamethoxazole, itraconazole, and others.

On the basis of end user, the market has been segmented into hospitals, clinical laboratories, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The chronic granulomatous disease market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European chronic granulomatous disease market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The chronic granulomatous disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The chronic granulomatous disease market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

Geographically, the Americas is anticipated to dominate the global chronic granulomatous disease market owing to a well-developed healthcare sector, rising prevalence of rare diseases, steady growing occurrence of chronic granulomatous disease (CGD), and relatively large number of research and development activities. According to an article published by the National Center for Biotechnology Information (NCBI) in 2017, the incidence of CGD in the US is around 1 in 200,000 to 1 in 250,000 births.

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.